Brief: CStone Announces European Medicine Agency CHMP Recommends Approval Of Cejemly As First-Line Treatment For NSCLC
01/06/2024 16:54
June 1 (Reuters) - CStone Pharmaceuticals 2616.HK :
* CSTONE ANNOUNCES EUROPEAN MEDICINE AGENCY CHMP RECOMMENDS
APPROVAL OF CEJEMLY® (SUGEMALIMAB, ANTI-PD-L1) AS FIRST-LINE
TREATMENT FOR NSCLC
Source text for Eikon: ID:nPregswnqa
Further company coverage: 2616.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026